Chinese drugmaker Ganzhou Hemay delays Hong Kong listing on market conditions

Nov 4 (Reuters) – Chinese drugmaker Ganzhou Hemay Pharmaceutical said on Wednesday that it has postponed its global offering and the planned listing on the Hong Kong stock exchange, citing current market conditions. Here are some more details: • Last week, the firm launched its global offering, aiming to raise about HK$1.04 billion ($132.56 million), at the maximum offer price of HK$18.9 per…

Open True Mainstream to compare left, right, and center coverage

1,600+ newsrooms tracked, in English, around the clock. Real newsrooms only — no NGOs, no press releases. Left/Right tags come from reader feedback. No algorithmic feed.